Put This Stock On Watch
Fast growing company in fast-growing wellness market starting to draw attention.

NASDAQ:GMTX - Gemini Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 234.35 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.58
▼ -0.11 (-1.64%)

This chart shows the closing price for GMTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gemini Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMTX

Analyst Price Target is $22.00
▲ +234.35% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gemini Therapeutics in the last 3 months. The average price target is $22.00, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 234.35% upside from the last price of $6.58.

This chart shows the closing price for GMTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Put This Stock On Watch
Fast growing company in fast-growing wellness market starting to draw attention.

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Gemini Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2021SVB LeerinkInitiated CoverageOutperform$25.00High
3/3/2021Jefferies Financial GroupInitiated CoverageBuy$23.00Low
3/2/2021The Goldman Sachs GroupInitiated CoverageBuy$20.00Low
2/16/2021Stifel NicolausInitiated CoverageBuy$20.00Low
(Data available from 6/24/2016 forward)
Gemini Therapeutics logo
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.58
Low: $6.52
High: $7.19

50 Day Range

MA: $11.07
Low: $6.69
High: $12.75

52 Week Range

Now: $6.58
Low: $6.50
High: $19.08

Volume

86,663 shs

Average Volume

323,386 shs

Market Capitalization

$283.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Gemini Therapeutics?

The following Wall Street analysts have issued stock ratings on Gemini Therapeutics in the last twelve months: Jefferies Financial Group Inc., Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for GMTX.

What is the current price target for Gemini Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Gemini Therapeutics in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 234.3%. SVB Leerink LLC has the highest price target set, predicting GMTX will reach $25.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $20.00 for Gemini Therapeutics in the next year.
View the latest price targets for GMTX.

What is the current consensus analyst rating for Gemini Therapeutics?

Gemini Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GMTX will outperform the market and that investors should add to their positions of Gemini Therapeutics.
View the latest ratings for GMTX.

What other companies compete with Gemini Therapeutics?

How do I contact Gemini Therapeutics' investor relations team?

Gemini Therapeutics' physical mailing address is C/O FORESITE CAPITAL 600 MONTGOMERY ST SUITE 4500, SAN FRANCISCO CA, 94111. The company's listed phone number is 617 678 3113 and its investor relations email address is [email protected] The official website for Gemini Therapeutics is www.geminitherapeutics.com.

Put This Stock On Watch
Fast growing company in fast-growing wellness market starting to draw attention.